@article{curry_belzutifan_2024,
	title = {Belzutifan: a novel therapeutic for the management of von {Hippel}-{Lindau} disease and beyond},
	volume = {20},
	issn = {1744-8301},
	shorttitle = {Belzutifan},
	doi = {10.2217/fon-2023-0679},
	abstract = {The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond. This review summarizes the history, pharmacology and clinical evidence for belzutifan use to date, and also explores unanswered questions as they relate to this novel therapeutic agent.},
	language = {eng},
	number = {18},
	journal = {Future Oncology (London, England)},
	author = {Curry, Lauren and Soleimani, Maryam},
	year = {2024},
	pmid = {38639572},
	pmcid = {PMC11318713},
	keywords = {Animals, Antineoplastic Agents, Basic Helix-Loop-Helix Transcription Factors, Carcinoma, Renal Cell, Clinical Trials as Topic, HIF-2α inhibitor, Humans, Kidney Neoplasms, Treatment Outcome, Von Hippel-Lindau Tumor Suppressor Protein, belzutifan, hemangioblastomas, kidney cancer, pancreatic neuroendocrine tumors, renal cancer, renal cell carcinoma, systemic therapy, von Hippel-Lindau Disease, von Hippel–Lindau disease},
	pages = {1251--1266},
}

{"_id":"Ri3jQpWzP5bB3fGhr","bibbaseid":"curry-soleimani-belzutifananoveltherapeuticforthemanagementofvonhippellindaudiseaseandbeyond-2024","author_short":["Curry, L.","Soleimani, M."],"bibdata":{"bibtype":"article","type":"article","title":"Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond","volume":"20","issn":"1744-8301","shorttitle":"Belzutifan","doi":"10.2217/fon-2023-0679","abstract":"The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond. This review summarizes the history, pharmacology and clinical evidence for belzutifan use to date, and also explores unanswered questions as they relate to this novel therapeutic agent.","language":"eng","number":"18","journal":"Future Oncology (London, England)","author":[{"propositions":[],"lastnames":["Curry"],"firstnames":["Lauren"],"suffixes":[]},{"propositions":[],"lastnames":["Soleimani"],"firstnames":["Maryam"],"suffixes":[]}],"year":"2024","pmid":"38639572","pmcid":"PMC11318713","keywords":"Animals, Antineoplastic Agents, Basic Helix-Loop-Helix Transcription Factors, Carcinoma, Renal Cell, Clinical Trials as Topic, HIF-2α inhibitor, Humans, Kidney Neoplasms, Treatment Outcome, Von Hippel-Lindau Tumor Suppressor Protein, belzutifan, hemangioblastomas, kidney cancer, pancreatic neuroendocrine tumors, renal cancer, renal cell carcinoma, systemic therapy, von Hippel-Lindau Disease, von Hippel–Lindau disease","pages":"1251–1266","bibtex":"@article{curry_belzutifan_2024,\n\ttitle = {Belzutifan: a novel therapeutic for the management of von {Hippel}-{Lindau} disease and beyond},\n\tvolume = {20},\n\tissn = {1744-8301},\n\tshorttitle = {Belzutifan},\n\tdoi = {10.2217/fon-2023-0679},\n\tabstract = {The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond. This review summarizes the history, pharmacology and clinical evidence for belzutifan use to date, and also explores unanswered questions as they relate to this novel therapeutic agent.},\n\tlanguage = {eng},\n\tnumber = {18},\n\tjournal = {Future Oncology (London, England)},\n\tauthor = {Curry, Lauren and Soleimani, Maryam},\n\tyear = {2024},\n\tpmid = {38639572},\n\tpmcid = {PMC11318713},\n\tkeywords = {Animals, Antineoplastic Agents, Basic Helix-Loop-Helix Transcription Factors, Carcinoma, Renal Cell, Clinical Trials as Topic, HIF-2α inhibitor, Humans, Kidney Neoplasms, Treatment Outcome, Von Hippel-Lindau Tumor Suppressor Protein, belzutifan, hemangioblastomas, kidney cancer, pancreatic neuroendocrine tumors, renal cancer, renal cell carcinoma, systemic therapy, von Hippel-Lindau Disease, von Hippel–Lindau disease},\n\tpages = {1251--1266},\n}\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Curry, L.","Soleimani, M."],"key":"curry_belzutifan_2024","id":"curry_belzutifan_2024","bibbaseid":"curry-soleimani-belzutifananoveltherapeuticforthemanagementofvonhippellindaudiseaseandbeyond-2024","role":"author","urls":{},"keyword":["Animals","Antineoplastic Agents","Basic Helix-Loop-Helix Transcription Factors","Carcinoma","Renal Cell","Clinical Trials as Topic","HIF-2α inhibitor","Humans","Kidney Neoplasms","Treatment Outcome","Von Hippel-Lindau Tumor Suppressor Protein","belzutifan","hemangioblastomas","kidney cancer","pancreatic neuroendocrine tumors","renal cancer","renal cell carcinoma","systemic therapy","von Hippel-Lindau Disease","von Hippel–Lindau disease"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/VHLA/5946245","dataSources":["ePsAR3pjtvuSxA4wN"],"keywords":["animals","antineoplastic agents","basic helix-loop-helix transcription factors","carcinoma","renal cell","clinical trials as topic","hif-2α inhibitor","humans","kidney neoplasms","treatment outcome","von hippel-lindau tumor suppressor protein","belzutifan","hemangioblastomas","kidney cancer","pancreatic neuroendocrine tumors","renal cancer","renal cell carcinoma","systemic therapy","von hippel-lindau disease","von hippel–lindau disease"],"search_terms":["belzutifan","novel","therapeutic","management","von","hippel","lindau","disease","beyond","curry","soleimani"],"title":"Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond","year":2024}